Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
investigational drug
|
| gptkbp:administeredBy |
adults
|
| gptkbp:alternativeName |
VOWST
|
| gptkbp:approvalYear |
April 2023
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:contains |
purified Firmicutes bacterial spores
|
| gptkbp:developedBy |
gptkb:Seres_Therapeutics
|
| gptkbp:firstBook |
yes
|
| gptkbp:form |
oral capsules
|
| https://www.w3.org/2000/01/rdf-schema#label |
SER-109
|
| gptkbp:indication |
prevention of recurrence of C. difficile infection in adults
|
| gptkbp:intendedUse |
prevention of recurrent Clostridioides difficile infection
|
| gptkbp:marketedAs |
gptkb:Seres_Therapeutics
|
| gptkbp:mechanismOfAction |
restoration of gut microbiome
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:type |
live biotherapeutic product
|
| gptkbp:bfsParent |
gptkb:Seres_Therapeutics
|
| gptkbp:bfsLayer |
7
|